Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell Carcinoma

Phase 3 Unknown 504 enrolled Biotech Pharmaceutical Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This clinical study is designed as a phase 3,multicenter, double-blind, randomized, controlled study,to evaluate the efficacy and safety of nimotuzumab combined with paclitaxel+cisplatin（TP) compared with TP as first-line treatment for the metastatic esophageal squamous carcinoma.

Timeline

Start: 2015-11
Primary completion: 2018-12
Completion: 2019-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Nimotuzumab	Monoclonal antibody	400 mg	—
Background	Cisplatin	Other / unclassified	60 mg/m2	—
Background	Paclitaxel	Small molecule	175 mg/m2	—

Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell Carcinoma

Summary

Timeline

Drugs

Indications